TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06030193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111 ophthalmic solution, (0.015%)
Description: QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-111 ophthalmic solution, (0.03%)
Description: QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QLS-111 ophthalmic vehicle solution
Description: Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Study: NCT04909515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: 3.0 mg/kg/day = 9.0 mg/kg/cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 - 500 microgram/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 160 mg/m2/day
Study: NCT05170399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afluria
Description: Annual Influenza Vaccine
Study: NCT05251636

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Episcleral Brachytherapy
Description: Minimally invasive, single fraction brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Standard of Care intravitreal aflibercept injection
Study: NCT05251636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: Standard of Care intravitreal aflibercept injection
Study: NCT06399016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: augmented reality book
Description: The story will be presented to the children in this application group in three dimensions. The augmented reality application will be supported by the researcher as it must be used under the supervision of an adult. When the tablet or phone is held to the pages of the book, the animations of these pages are displayed on the screen with sound. While the animation opens automatically when we hold the phone or tablet, the story can be listened to aloud at the same time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: book
Description: This group will be asked to just read the book without turning on the augmented reality feature of the book.
Study: NCT06435039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 IR tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 IR tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 IR tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 IR tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501
Description: APL-1501 ER capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501
Description: APL-1501 ER capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501
Description: APL-1501 ER capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501
Description: APL-1501 ER capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501
Description: APL-1501 ER capsules.
Study: NCT05214209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital health supported
Description: Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
Study: NCT05573256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation
Description: Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation
Description: Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education
Description: Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education
Description: Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
Study: NCT04714645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR neglect training
Description: Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR control training
Description: Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
Study: NCT05519085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT05198674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Symplicity Spyral™)
Description: Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Study: NCT04790370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation with heparin
Description: Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation with heparin
Description: Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EkoSonicTM Endovascular System
Description: EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
Study: NCT06225414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Patient Education
Description: Brief one-page education material on lung cancer screening benefits and risk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to financial navigation resources
Description: Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reminders
Description: within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Reminders
Description: Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
Study: NCT05782907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Tablets
Study: NCT05677139

Intervention type: OTHER
Intervention: None (Observational Study)
Description: Not applicable since it's an observational study.
Study: NCT05773573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
Study: NCT05476354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine low
Description: Irbesartan/Amlodipine low once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine high
Description: Irbesartan/Amlodipine high once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan once daily for 8 weeks
Study: NCT05464420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Study: NCT06084780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intestinal, Multivisceral or Modified Multivisceral Transplantation
Description: Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
Study: NCT05464420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study: NCT06378203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA)
Description: A personalized exercise plan following macro-areas of objectives:~* maintenance of muscle lengths with selective and/or prolonged static stretching exercises;~* maintenance/improvement of muscle trophism with selective and/or postural and/or functional muscle recruitment exercises at moderate intensity (approximately 65%-70% of the maximum);~* maintenance of respiratory muscle weakness with thoracic and/or diaphragmatic breathing exercises combined with muscle exercise;~* endurance training with walking, cycle ergometer (to be used with both the upper and lower limbs) and treadmill at moderate intensity (approximately 65%-70% of the maximum).~Home treatment will mostly take place with the KHYMEIA tele-rehabilitation system.
Study: NCT04322084

Intervention type: OTHER
Intervention: Wearable Sensors
Description: To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
Study: NCT04877990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study: NCT05264909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Transcranial direct current stimulation
Description: A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
Study: NCT05346354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight.
Study: NCT06015230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose GR1603 in phase Ⅰb
Description: 6 subjects in GR1603 low dose，2 subjects in placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose GR1603 in phaseⅠb
Description: 6 subjects in GR1603 high dose，2 subjects in placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose GR1603 in phase Ⅱ
Description: low dose GR1603 monthly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose GR1603 in phase Ⅱ
Description: high dose GR1603 monthly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in phase Ⅱ
Description: Placebo
Study: NCT04875780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital diabetes prevention app intervention
Description: 16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital weight loss tracking app intervention
Description: All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list control (usual care)
Description: Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
Study: NCT06084780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
Study: NCT06102902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT05002569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab Fixed Dose Combination
Description: Specified dose on specified days
Study: NCT05891119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous injection